Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Biotechnology

Healthcare
$10.19 -1.58%

-$0.19 today

Market cap
$859.56M
Beta
0.84
P/E (TTM)
-24.1
EPS (TTM)
-$0.49
52W Low $3.55High $26.95

Volume 0.99M

Average 1.49M

CRVS Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Corvus Pharmaceuticals, Inc.NASDAQ: CRVS

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$29K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$55K.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$29K or moves back toward the trailing-twelve-month quarterly average of -$13.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$29K-11.5% QoQ
Last fiscal yearDec 2025
-$105K— YoY
LTMMar 2026
-$55K— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
(105K) USD
Year-over-year change
—

Gross Profit vs competitors

How CRVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
CRVS Competitors
Gross Profit for CRVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCUSArcus Biosciences, Inc.LTM Jun 2026$110M USD-58.0%+28.4%94.0%
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M USD+16.2%-9.3%69.9%
CGENCompugen Ltd.LTM Mar 2026$63.98M USD+230.5%+113.5%88.1%
NKTRNektar TherapeuticsLTM Jun 2026$54.24M USD-13.2%-7.8%99.4%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$35.29M USD-76.1%+12.8%99.3%
CHRSCoherus Oncology, Inc.LTM Mar 2026$28.15M USD-74.3%-44.2%60.0%
IPHAInnate Pharma S.A.FY2025€2.79M EUR-77.9%-22.6%100.0%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$55K USD———
ADAGAdagene Inc.LTM Jun 2024-$118.77K USD—-6.2%14.6%
CMPXCompass Therapeutics, Inc.LTM Mar 2026-$738K USD-186.8%——
Peer median (excluding CRVS) —-66.2%-7.0%91.0%

Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0000105K
Gross Profit0000(105K)
Gross Margin—————
Research & Development29.12M24.47M16.53M19.39M33.72M
Selling, General & Admin9.52M8.1M6.88M8.16M9.25M
Operating Expenses38.63M32.57M23.41M27.55M42.87M
Depreciation & Amortization460K367K151K85K105K
EBITDA(42.77M)(40.94M)(26.88M)(62.21M)(15.18M)
EBITDA Margin—————
Operating Income(38.63M)(32.57M)(23.41M)(27.55M)(42.97M)
Operating Margin—————
Interest Income0654K1.58M1.82M2.51M
Interest Expense15K0000
Other Income / Expenses(4.61M)(8.74M)(3.62M)(34.75M)27.69M
Income Before Tax(43.24M)(41.31M)(27.03M)(62.29M)(15.28M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(43.24M)(41.31M)(27.03M)(62.29M)(15.28M)
Net Margin—————
EPS (Basic)(1.03)(0.89)(0.56)(1.02)(0.19)
EPS (Diluted)(1.03)(0.89)(0.56)(1.02)(0.53)
Weighted Avg Shares41.85M46.55M48.03M60.99M78.96M
Weighted Avg Shares (Diluted)41.85M46.55M48.03M60.99M79.74M

Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Intrinsic Alpha fair value

Locked

Current Price

$10.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.